Avantor Stock Price, News & Analysis

Avantor (NYSE: AVTR), a leading global provider of mission-critical products and services for life sciences and advanced technology industries, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Michael Stubblefield, President and CEO, will deliver a presentation at The Westin St. Francis Hotel in San Francisco on January 15, 2025, at 8:15 a.m. Pacific Standard Time.

Interested parties can access a live audio webcast of the session through the Events & Presentations section in the Investor area of Avantor's website at ir.avantorsciences.com. The webcast recording will remain available for replay for 30 days following the presentation.

Avantor (NYSE: AVTR), a global provider of mission-critical products and services for life sciences and advanced technology industries, announced its participation in the 7th Annual Evercore ISI HealthCONx Conference. President and CEO Michael Stubblefield will join a fireside chat on December 3 at 9:10 a.m. EST in Coral Gables, Florida.

The session will be available via live audio webcast through the Events & Presentations section of Avantor's investor website, with a replay accessible for 30 days following the event.

Quantum-Si (Nasdaq: QSI) has entered into a distribution agreement with Avantor (NYSE: AVTR) for its Next-Generation Protein Sequencing (NGPS) technology portfolio in the U.S. and Canadian markets. The collaboration will enable broader access to QSI's proteomics solutions across various laboratory settings. The platform utilizes single-molecule sequencing technology for protein and biomarker identification, antibody characterization, protein barcoding, and post-translational modification analysis, supporting applications in drug discovery, diagnostics, and clinical research.

Avantor (NYSE: AVTR) announced the opening of its new flagship Bridgewater Innovation Center in New Jersey. The 60,000-square-foot facility doubles the previous laboratory and pilot plant capacity, featuring dedicated spaces for upstream and downstream process development, analytical testing labs, and a viral vector laboratory. The center, part of Avantor's global network of 13 research facilities, is staffed with Ph.D. scientists, bioengineers, and process engineers to support biomanufacturing optimization and accelerate development of therapies including monoclonal antibodies, cell and gene therapy, and mRNA workflows.

Avantor (NYSE: AVTR) has appointed Dame Louise Makin to its Board of Directors, effective until the 2025 Annual Meeting of Stockholders. Dame Louise, former CEO of BTG plc for 15 years, brings significant healthcare industry experience, having led BTG's transformation through organic growth and acquisitions until its acquisition by Boston Scientific in 2019. She previously held leadership positions at Baxter Healthcare, including President of Biopharmaceuticals Europe. Currently, she serves as non-executive chair of Halma plc and has served on multiple corporate boards. Dame Louise holds a Ph.D. in material sciences from Cambridge and an MBA from The Open University.

Avantor (NYSE: AVTR) reported Q3 2024 financial results with net sales of $1.71 billion, showing a slight decrease of 0.3% (0.7% organic decline). Net income decreased to $57.8 million from $108.4 million in Q3 2023, with diluted EPS of $0.08 and adjusted EPS of $0.26. The company achieved strong free cash flow of $204.0 million, leading to increased full-year guidance. Laboratory Solutions segment saw 1.1% growth, while Bioscience Production decreased by 3.2%. The company maintains its outlook for mid to high single-digit growth in bioprocessing, with cost transformation programs running ahead of plan.

Avantor (NYSE: AVTR) has expanded its partnership with the National Institute for Bioprocessing Research and Training (NIBRT) to address biopharma manufacturing challenges. The collaboration focuses on downstream optimization for monoclonal antibodies (mAbs) through advanced equipment provision and specialized training. Avantor will supply Masterflex® pump systems and single-use systems to create realistic biopharmaceutical workflows in NIBRT's training facilities. The partnership aims to tackle scale-up challenges, optimize fluid handling processes, and enhance manufacturing efficiency through expert-led training sessions.

Audax Private Equity has completed the acquisition of Avantor, Inc.'s (NYSE: AVTR) clinical services business, rebranding it as Resonant Clinical Solutions. Resonant comprises three established brands: EPL Archives, MESM, and Therapak, which provide comprehensive services to pharmaceutical, biotechnology, CRO, and diagnostic laboratory customers.

Audax plans to drive organic and inorganic growth for Resonant, enhancing existing solutions and adding complementary capabilities through M&A. The company aims to capitalize on the increasing complexity of clinical trial services, which is driving outsourcing to specialists like Resonant.

Moelis & Company and Ropes & Gray LLP advised Audax, while J.P. Morgan Securities and Arnold & Porter advised Avantor in the transaction.

Avantor (NYSE: AVTR) has closed the divestiture of its clinical services business to Audax Private Equity for approximately $650 million. The transaction is expected to yield $500 million in after-tax cash proceeds and reduce capitalized leases by about $50 million. Avantor plans to use the proceeds to pay down debt.

CEO Michael Stubblefield stated that this move will strengthen the company's balance sheet, reduce interest expenses, and allow focus on strategic growth in lab and production businesses. J.P. Morgan Securities and Arnold & Porter LLP advised Avantor, while Moelis & Company and Ropes & Gray LLP advised Audax in the transaction.